Monthly Archives: December 2020

Company announcement – No. 63 / 2020

The rest is here:
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated...

Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1

Go here to see the original:
Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1

Publication of Supplementary Prospectus

Read more:
Publication of Supplementary Prospectus

Eliminating one of the convertible notes represents a significant milestone for Global WholeHealth Partners Corp.

Follow this link:
Global WholeHealth Partners Corp (OTC: GWHP) Has Paid Off One of Its Outstanding Convertible Notes

- Single Trial to be Conducted in Patients with Fragile X Syndrome to Confirm Positive Results Seen in the Population of Responders in the CONNECT-FX Trial -

View original post here:
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome

BERWYN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced an interview with its CEO, Maria Maccecchini, Ph.D., will air on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International.

More here:
Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report

GSK will have exclusive rights to develop and commercialize SRF813, a novel antibody targeting PVRIG

Follow this link:
Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program

BURLINGAME, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (NASDAQ: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: NBI). ALX’s addition to the NBI will become effective prior to market open on Monday, December 21, 2020.

See more here:
ALX Oncology Added to the NASDAQ Biotechnology Index

QuantuMDx embarks on £11 million scale-up to mass manufacture its diagnostic Q-POCTM device and disposable test cassette

Excerpt from:
QuantuMDx embarks on £11 million scale-up to mass manufacture its diagnostic Q-POCTM device and disposable test cassette

Company Anticipates NDA Resubmission in February 2021 Company Anticipates NDA Resubmission in February 2021

Read the rest here:
Avenue Therapeutics Provides Regulatory Update for IV Tramadol